Why Retatrutide Causes Constipation
Constipation on retatrutide is a direct consequence of the same mechanism that produces weight loss. GLP-1 receptor activation slows gastric emptying — the stomach releases food into the small intestine more slowly, which reduces appetite. The same slowing effect extends through the entire digestive tract, reducing the motility of the intestines. Food moves through the colon more slowly, which means more water is absorbed from the stool, making it harder and more difficult to pass. In the Phase 2 trial published in the New England Journal of Medicine in 2023, constipation was reported by 15-20% of participants, making it the third most common side effect after nausea and diarrhea.
How Constipation Compares Across GLP-1 Drugs
Constipation rates for retatrutide are 15-20%, which is comparable to tirzepatide at 12-17% and slightly higher than semaglutide at 10-14% in their respective Phase 3 trials. The slightly higher rate may relate to the additional glucagon receptor activation, which can affect gastrointestinal motility through independent pathways. The constipation is typically mild to moderate and most common during dose escalation. The TRIUMPH protocols use four-week intervals between dose increases specifically to allow the digestive system time to adapt.
Practical Strategies for Relief
Increasing fluid intake is the first and most effective strategy. GLP-1 drugs reduce appetite and thirst, which can lead to dehydration that worsens constipation. Aim for at least 2 to 3 liters of fluid per day. Increasing soluble fiber intake — oats, apples, psyllium husk — can help by drawing water into the stool. If dietary changes are insufficient, over-the-counter options include polyethylene glycol, which is generally well tolerated and does not interact with GLP-1 receptor activation. Stimulant laxatives should be used sparingly, as they can cause cramping that compounds the gastrointestinal side effects of retatrutide.
When Constipation Becomes a Problem
Constipation that persists for more than 5 days despite increased fluid and fiber intake warrants medical attention. Severe constipation with abdominal pain, vomiting, or inability to pass gas may indicate a bowel obstruction, which requires immediate medical evaluation. In the clinical trials, no cases of serious constipation-related complications were reported, but the rate of discontinuation due to gastrointestinal side effects was approximately 10%, and constipation was a contributing factor for some participants.
Prevention During the Titration Phase
The best approach to constipation on retatrutide is prevention during the dose escalation period. Starting a fiber supplement before increasing the dose, maintaining high fluid intake, and keeping physical activity levels up can all reduce the likelihood of constipation becoming severe enough to require treatment. The graduated dosing schedule — 2 mg for 4 weeks, then 4 mg for 4 weeks — is designed to give the digestive system time to adapt. Rushing the titration increases the risk of both constipation and other gastrointestinal side effects.
Leave a Reply